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subgroup	 of	 colorectal	 cancers	 (CRC).	 This	 genomic	 and	 transcriptomic	 analysis	 of	 the	 cetuximab	
resistance	 landscape	 in	 35	 RAS	 wild-type	 CRCs	 identified	 associations	 of	 NF1	 and	 non-canonical	
RAS/RAF-aberrations	 with	 primary	 resistance	 and	 validated	 transcriptomic	 CRC-subtypes	 as	 non-
genetic	 predictors	 of	 benefit.	 64%	 of	 biopsies	 with	 acquired	 resistance	 harbored	 no	 genetic	
resistance	drivers.	Most	of	these	had	switched	from	a	cetuximab-sensitive	transcriptomic	subtype	at	
baseline	 to	 a	 fibroblast-	 and	 growth	 factor-rich	 subtype	 at	 progression.	 Fibroblast-supernatant	
conferred	cetuximab	resistance	 in	vitro,	confirming	a	major	role	for	non-genetic	resistance	through	
stromal	 remodelling.	 Cetuximab	 treatment	 increased	 cytotoxic	 immune	 infiltrates	 and	 PD-L1	 and	
LAG3	 immune-checkpoint	 expression,	 potentially	 providing	 opportunities	 to	 treat	 cetuximab-
resistant	CRCs	with	immunotherapy.	
SIGNIFICANCE	
	 Only	43%	of	patients	had	prolonged	benefit	 from	cetuximab	 in	 this	 trial	despite	treatment	
stratification	 by	 RAS	mutations.	 The	 identified	 associations	 of	NF1,	 non-canonical	KRAS	 and	BRAF	
aberrations	with	primary	resistance	and	of	CMS2/TA	transcriptomic	subtypes	with	prolonged	benefit	
may	 enable	 more	 effective	 treatment	 allocation	 and	 avoid	 toxicities	 from	 ineffective	 therapy.	
Genetic	 resistance	 drivers	 were	 not	 identified	 in	 the	 majority	 of	 metastases	 that	 had	 acquired	
resistance.	 Most	 of	 these	 had	 switches	 from	 the	 cetuximab	 sensitive	 CMS2/TA-subtype	 to	 a	
fibroblast-	 and	 growth	 factor-rich	 subtype.	 This	 challenges	 the	 paradigm	 that	 genetic	 drivers	
predominate	 at	 acquired	 resistance	 and	 suggests	 therapeutic	 approaches	 by	 targeting	 fibroblasts.	











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































No RNA sequencing data
Low confidence classification
Patients treated (n=35)
Prolonged Benefit 42.9% (n=15) Clinical benefit
Sidedness
CMS subtype
Primary Progression 57.1% (n=20) 





















73% TA subtype 21% TA subtype 
82% CMS2 subtype 29% CMS2 subtype
 p=0.017
 p=0.015
Prolonged benefit Primary progression



